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Patients who test positive for hepatitis C virus (HCV) antibody are not considered suitable living kidney
donor candidates for HCV negative recipients. Here, we report a case of an HCV positive patient treated
successfully with antiviral therapy, achieving sustained virologic response (SVR), who subsequently
donated a kidney to an HCV negative recipient without viral transmission. This suggests that HCV po-
sitive patients who achieve SVR may safely donate kidneys.
A 66-year-old male with end-stage renal disease had been on hemodialysis for 7 years. His 63-year-
old wife was a candidate for living donation, but had a history of HCV infection. She had received in-
terferon-beta treatment 12 years previously. After the treatment, SVR was achieved and her liver en-
zymes were normalized. The recipient received a preconditioning regimen comprising a single dose of
rituximab combined with cyclosporine microemulsion and mycophenolate mofetil 2 weeks before the
transplantation for the desensitization of anti-blood type antibody. The operation was performed with no
adverse events. Protocol kidney biopsies at 3 and 12 months showed no signs of rejection. The recipient's
liver function tests remained within the normal range, HCV antibody testing was negative, and HCV RNA
was undetectable at the 1-year follow-up. At the time of this writing, the recipient is healthy with a
serum creatinine level of 1.2 mg/dL. Likewise, the donor is healthy with follow up indicating SVR, normal
liver enzymes, and normal renal function.
In conclusion, only in selected cases, HCV antibody positive donors may be taken into consideration
as a kidney donor.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Renal transplantation is an optimal choice of treatment and a
lifesaving procedure for end stage renal disease and is practiced
worldwide. However, the shortage of well-matched living donors
remains a signiﬁcant problem. It is now considered acceptablen open access article under the C
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donor into a patient with known HCV infection [1]. Renal trans-
plantation from HCV positive donors to HCV negative recipients,
however, is not considered safe due to the chance of HCV trans-
mission, which may further lead to liver disease and liver dys-
function. However, it should be considered that the potential risk
of death in these patients without transplantation likely out-
weighs the risk of viral transmission. HCV can now be completely
treated with the use of antiviral therapy that consists of interferon
and directly-acting antiviral agents (DAA) [2]. It is conceivable that
a successfully treated HCV patient, who has achieved SVR, may
serve as a kidney donor for a hepatitis C negative recipient without
viral transmission. Here, we report a case of an HCV positive pa-
tient treated successfully with antiviral therapy who subsequently
donated a kidney to an HCV negative recipient without viral
transmission.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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A 66-year-old man, blood type B, with end-stage renal disease
due to autosomal dominant polycystic kidney disease had been on
hemodialysis for 7 years. His 63-year-old wife, blood type A, was a
candidate for living donation. She had a history of genotype 2a
HCV infection with moderate chronic hepatitis and severe ﬁbrosis
(A2/F3; New Inuyama classiﬁcation) and had received interferon-
beta treatment 12 years previously. After the treatment, SVR and
normalization of liver enzymes were achieved. Approval was ob-
tained from the institutional review board of the Hiroshima Uni-
versity Hospital and informed consent was obtained from both the
donor and the recipient. The recipient was given a preconditioning
regimen consisting of a single dose of rituximab (375 mg/m2)
combined with cyclosporine microemulsion (target trough level:
50–100 ng/ml) and mycophenolate mofetil (500 twice daily)
2 weeks before the transplant for the desensitization of anti-blood
type antibody. As anti-blood type isoagglutinin titers were below
1:16, double-ﬁltration plasmapheresis was not required.
After extensive discussion during multidisciplinary rounds,
everyone involved with the patient-care team agreed that it was
safe to proceed. The operation was performed with no adverse
events. Induction quadruple immunosuppression protocol con-
sisted of cyclosporine microemulsion, mycophenolate mofetil,
basiliximab and methylprednisolone. After transplantation, the
patient's immune status was evaluated regularly by a mixed
lymphocyte reaction using intracellular carboxyﬂuorescein diace-
tate succinimidyl ester (CFSE-MLR assay) and immunosuppressant
therapy was optimized accordingly [3,4]. Protocol kidney biopsies
performed at 3 and 12 months showed no signs of rejection. The
recipient's liver function tests remained within the normal range,
HCV antibody testing was negative, and HCV RNA was un-
detectable at the 1-year follow-up. At the time of this writing, the
recipient is healthy with a serum creatinine level of 1.2 mg/dL. The
donor is also doing well; follow up showed SVR, normal liver
enzymes, and normal renal function without hypertension, pro-
teinuria, or microhematuria.3. Discussion
The disparity between organ demand and supply in renal
transplantation remains a signiﬁcant problem. Reports indicate
that in order to address this problem, grafts from donors with
active infections were used, after giving proper antibiotic pro-
phylaxis, and that outcomes were similar to those with organs
from non-infected donors [5]. Similarly, there have been additional
reports which suggest that in addition to the normal expanded
criteria, donors with advanced age, obesity, hypertension, de-
creased GFR, proteinuria and microscopic hematuria or with fur-
ther anatomical speciﬁcations such as obstruction at the ureter-
opelvic junction, kidney stones, renal cysts, and complex vascular
anatomy should also be evaluated as donor candidates in order to
increase the number of potential donors [6].
Regarding expansion of the donor pool, ABO incompatible liv-
ing kidney transplantation has been performed for decades to
address the serious shortage of organ donors, especially in eastern
countries. Some reports suggest that because of newer pre-
conditioning therapy, almost 30% total living donor kidney trans-
plants done in Japan are ABO incompatible cases, and outcomes
are excellent [7]. With the help of desensitization modalities and
modern immunosuppression, there is not much difference be-
tween graft and patient survival between ABO incompatible and
ABO compatible renal transplantation. Indeed, with the effective-
ness of modern day immunosuppression, living donor ABO in-
compatible renal transplantation is a viable alternative to deceaseddonor transplantation [8,9].
Due to the global organ shortage, the KDIGO guidelines re-
commend using kidneys from HCV positive donors in HCV-posi-
tive recipients. However, it is also accepted that HCV positive
grafts should not be used in HCV negative recipients, since the risk
of HCV transmission approaches 100%. Following renal trans-
plantation, patients with HCV infection have an elevated risk of
developing proteinuria, chronic allograft nephropathy, secondary
infection, new-onset diabetes, transplant glomerulopathy, and
neoplasia. The increased mortality observed among patients with
HCV infection is largely the result of a high incidence of cardio-
vascular disease, other infections, and liver disease.
However, over the last 25 years, therapy for HCV has become
highly successful, with SVR increasing steadily since the in-
troduction of IFNα monotherapy, then by the addition of ribavirin,
and later by pegylated IFN pegylated interferon-α (PEG-IFN-α)
[10,11]. Recently, anti-HCV therapy was further improved by the
approval of direct-acting antivirals (DAAs). Reports suggest that
with the highly effective treatment of HCV by new DAAs, the
management of HCV has signiﬁcantly improved and that un-
detectable HCV RNA 12 weeks after treatment withdrawal have
been identiﬁed to be cure for HCV now [2]. Almost 99% patients
who have achieved SVR after antiHCV treatment remain virus-free
for a longer period of time [10]. Another study conducted in the
Japanese population found that patients who achieved SVR after
antiviral treatment in liver transplant patient with recurrent HCV
had prolonged and better survival compared to those who did not
achieve SVR [11].
Under these circumstances, it is not known if the patients have
achieved SVR, they probably deserve consideration for living kid-
ney donors, but there have been very few reports of successful
transplants in this situation. Bouatou et al. recently reported the
ﬁrst successful case of ABO incompatible kidney transplantation
from an HCV antibody positive, HCV RNA negative donor to an
HCV antibody negative recipient [12]. The recipient had no liver
disease or acute HCV infection at 1 year of follow up. In this case,
the donor seemed to have achieved SVR spontaneously. We report
our case with detailed history of donor's HCV treatment and that
achievement of SVR with HCV RNA undetectable 12 years after the
ﬁrst treatment. This allowed us to consider this candidate as po-
tential donor for our recipient.
Similar reports from Cruzado et al. suggest that successfully
treated chronic HCV infection should not preclude an individual
from donating a kidney to an HCV negative recipient [13]. The
donor is this case had a long history of chronic hepatitis C and was
treated for 1 year with antiviral therapy before transplantation
was done. HCV viral load in the recipient was negative even
2 years after transplantation. Another small cohort study done by
Rozental et al. showed that HCV negative recipients who received
kidneys from HCV positive deceased donors had better survival
with less rejection compared to HCV positive recipients who re-
ceived kidneys from HCV positive donors early in the transplant
period [14].
Here, we report a case of an HCV positive patient treated suc-
cessfully with antiviral therapy who subsequently donated a kid-
ney to an HCV negative recipient without viral transmission.
However, there is an ethical concern in using a kidney from a
living donor who, in spite of SVR, theoretically might have a risk of
relapse. Furthermore, the donor kidney may harbor HCV virus
even after the patient has achieved SVR, so the theoretical possi-
bility of HCV transmission cannot be ruled out. Although our ob-
servation suggests a possible way to increase the living donor pool
for kidney transplantation, longitudinal studies with close clinical
and virologic monitoring of donors and recipients will be required
to investigate the safety of widespread kidney donation from HCV
antibody positive donors who have achieved SVR (Fig. 1).
Fig. 1. Changes in serum creatinine, ALT, and proﬁles of anti-HCV and HCV-RNA
after transplantation.
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In conclusion, only in selected cases, HCV antibody positive
donors may be taken into consideration as a kidney donor.Disclosure
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